<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bluejay Diagnostics Inc — News on 6ix</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc</link>
<description>Latest news and press releases for Bluejay Diagnostics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bluejay-diagnostics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354d9178dffbe2df0e6002.webp</url>
<title>Bluejay Diagnostics Inc</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc</link>
</image>
<item>
<title>Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-inc-announces-completion-of-624-patient-enrollments-in-symon-ii-pivotal-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-inc-announces-completion-of-624-patient-enrollments-in-symon-ii-pivotal-clinical-trial</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid,</description>
</item>
<item>
<title>Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-announces-abstract-accepted-for-presentation-at-the-2026-society-of-academic-emergency-medicine-saem-annual-meeting-5</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-announces-abstract-accepted-for-presentation-at-the-2026-society-of-academic-emergency-medicine-saem-annual-meeting-5</guid>
<pubDate>Thu, 12 Mar 2026 10:30:00 GMT</pubDate>
<description>New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual M</description>
</item>
<item>
<title>Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-provides-corporate-update-and-2026-strategic-outlook-6</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-provides-corporate-update-and-2026-strategic-outlook-6</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company</description>
</item>
<item>
<title>Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-all-prefunded-warrants-now-exercised</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-all-prefunded-warrants-now-exercised</guid>
<pubDate>Fri, 20 Feb 2026 11:30:00 GMT</pubDate>
<description>ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outst</description>
</item>
<item>
<title>Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-successfully-enrolls-545-113000906</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-successfully-enrolls-545-113000906</guid>
<pubDate>Tue, 17 Feb 2026 11:30:00 GMT</pubDate>
<description>ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the Company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness. SYMON-II Clinical trial</description>
</item>
<item>
<title>Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-1-4-130000986</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-1-4-130000986</guid>
<pubDate>Tue, 27 Jan 2026 13:00:00 GMT</pubDate>
<description>ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-completion-commercial-120000874</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-completion-commercial-120000874</guid>
<pubDate>Mon, 29 Dec 2025 12:00:00 GMT</pubDate>
<description>ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a biomarker relevant to inflammatory and critical-care applications. The Company stated that both polyclonal and monoclonal antibodies met internal performance criteria, including reactivity, for use in Symphony™ cartridge manufacturing intended</description>
</item>
<item>
<title>Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-corporate-advancing-clinical-123000564</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-corporate-advancing-clinical-123000564</guid>
<pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
<description>Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization.Patient enrollment in SYMON-II clinical trial now approximately 50% completed.Recent private placement transaction completed in October 2025; Company continues to explore further financing opportunities. ACTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical dia</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-closing-4-211600931</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-closing-4-211600931</guid>
<pubDate>Fri, 10 Oct 2025 21:16:00 GMT</pubDate>
<description>ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per</description>
</item>
<item>
<title>Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-4-5-191500932</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-4-5-191500932</guid>
<pubDate>Thu, 09 Oct 2025 19:15:00 GMT</pubDate>
<description>ACTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,250,000 shares of common stock (or pre-funded warrant in lieu thereof) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per share of co</description>
</item>
<item>
<title>Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-sanyoseiko-expand-strategic-103000170</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-sanyoseiko-expand-strategic-103000170</guid>
<pubDate>Thu, 09 Oct 2025 10:30:00 GMT</pubDate>
<description>ACTON, Mass. and YAMANASHI, Japan, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), a medical diagnostics company focused on developing rapid near-patient testing solutions for critical care, today announced that it has entered into an Agreement to Amend the Master Service Agreement and the Master Supply Agreement with SanyoSeiko Co., Ltd. (“SanyoSeiko”), a Japan-based contract manufacturer specializing in medical devices and precision engineering. The amen</description>
</item>
<item>
<title>Bluejay Diagnostics Provides Second Quarter Business and Corporate Update</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-provides-second-quarter-223000235</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-provides-second-quarter-223000235</guid>
<pubDate>Thu, 07 Aug 2025 22:30:00 GMT</pubDate>
<description>ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones. Second Quarter 2025 and Recent Corporate Highlights SYMON-II Pivotal Clinical Study Underway: Bluejay has initiated patient enrollment in</description>
</item>
<item>
<title>Bluejay Diagnostics Provides Mid-Year Business and Corporate Update</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-provides-mid-business-200500864</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-provides-mid-business-200500864</guid>
<pubDate>Tue, 03 Jun 2025 20:05:00 GMT</pubDate>
<description>ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: SYMON Clinical Program Update: The Company has initiated its pivotal SYMON-II clinical study, following the successful completion of the SYMON-I pilot study, for which a primary</description>
</item>
<item>
<title>Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-announces-abstract-accepted-presentation-110000149</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-announces-abstract-accepted-presentation-110000149</guid>
<pubDate>Tue, 15 Apr 2025 11:00:00 GMT</pubDate>
<description>New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented.ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6)</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-entry-warrant-212100117</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-entry-warrant-212100117</guid>
<pubDate>Mon, 07 Apr 2025 21:21:00 GMT</pubDate>
<description>ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exe</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Reverse Stock Split</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-reverse-stock-split</guid>
<pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
<description>ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-closing-of-dollar875-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-closing-of-dollar875-million-underwritten-public-offering</guid>
<pubDate>Fri, 28 Jun 2024 04:00:00 GMT</pubDate>
<description>ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-pricing-of-dollar875-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-pricing-of-dollar875-million-underwritten-public-offering</guid>
<pubDate>Thu, 27 Jun 2024 04:00:00 GMT</pubDate>
<description>ACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-closing-of-dollar35-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-closing-of-dollar35-million-public-offering</guid>
<pubDate>Tue, 02 Jan 2024 05:00:00 GMT</pubDate>
<description>ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing</description>
</item>
<item>
<title>Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering</title>
<link>https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-pricing-of-dollar35-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/bluejay-diagnostics-inc/news/bluejay-diagnostics-announces-pricing-of-dollar35-million-public-offering</guid>
<pubDate>Thu, 28 Dec 2023 05:00:00 GMT</pubDate>
<description>ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing</description>
</item>
</channel>
</rss>